MGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia

Schizophrenia Research

Volumn 136, Issue 1-3, 2012, Pages 160-161

  Olszewski, Rafal T ^a   Bzdega, Tomasz ^a   Neale, Joseph H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; LETTER; MEDIATOR RELEASE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; VALIDATION PROCESS;

ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; GLUTAMATE CARBOXYPEPTIDASE II; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; ORGANOPHOSPHORUS COMPOUNDS; PHENCYCLIDINE; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 84858001721     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.01.007     Document Type: Letter

References (10)

1. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGluR3 receptors in the preclinical antipsychotic pharmacology of the mGluR2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 2008, 326:209-217.
2. Krystal J.H., Mathew S.J., D'Souza D.C., Garakani A., Gunduz-Bruce H., Charney D.S. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010, 24:669-693.
3. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
4. Neale J.H. N-Acetylaspartylglutamate (NAAG) is an agonist at mGluR3 in vivo and in vitro. J. Neurochem. 2011, 119:891-895.
5. Neale J.H., Olszewski R.T., Zuo D., Janczura K.J., Profaci C.P., Lavin K.M., Madore J.C., Bzdega T. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J. Neurochem. 2011, 118:490-498.
6. Olszewski R.T., Bukhari N., Zhou J., Kozikowski A.P., Wroblewski J.T., Shamimi-Noori S., Wroblewska B., Bzdega T., Vicini S., Barton F.B., Neale J.H. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J. Neurochem. 2004, 89:876-885.
7. Olszewski R.T., Wegorzewska M.M., Monteiro A.C., Krolikowski K.A., Zhou J., Kozikowski A.P., Long K., Mastropaolo J., Deutsch S.I., Neale J.H. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol. Psychiatry 2008, 63:86-91.
8. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGluR2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
9. Profaci C.P., Krolikowski K.A., Olszewski R.T., Neale J.H. Group II mGluR Agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and d-Amphetamine models of schizophrenia. Psychopharmacology 2011, 216:235-243.
10. Woolley M.L., Pemberton D.J., Bate S., Corti C., Jones D.N. The mGluR2 but not the mGluR3 receptor mediates the actions of the mGluR2/3 agonist, LY3799268, in mouse models predictive of antipsychotic activity. Psychopharmacology 2008, 196:431-440.